BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Biogen ( NASDAQ:BIIB )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biogen ( BIIB ) To Contact Him Directly To Discuss Their Options
Why Is Biogen Stock Climbing Wednesday? - Biogen ( NASDAQ:BIIB )
Biogen CEO says Novo Nordisk's Alzheimer's success could lead to combined drug trials. Novo Nordisk's late-stage Alzheimer's trial results are expected later this year. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → Biogen Inc.
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Stoke Therapeutics ( NASDAQ:STOK ) , Biogen ( NASDAQ:BIIB )
- Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - - Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that ...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
- Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period ...
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - Vor Biopharma ( NASDAQ:VOR )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio VOR, a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately.
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities ...
Sage ( SAGE ) Q2 Revenue Jumps 264%
Sage Therapeutics ( NASDAQ:SAGE ) , a biopharmaceutical company focused on developing medicines for brain health disorders, released its second quarter 2025 results on July 30, 2025. The most important news from the quarter was the significant revenue beat, as sales reached $31.7 million ( GAAP ) ...
Ionis ( IONS ) Q2 Revenue Soars 101%
Ionis Pharmaceuticals ( NASDAQ:IONS ) , a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates.
Why Is Biogen Stock Gaining Thursday? - Biogen ( NASDAQ:BIIB )
Q2 EPS of $5.47 beats $4.06 estimate; sales rose 7% YoY to $2.65 billion, topping $2.32 billion forecast. Leqembi sales jumped 20% QoQ; Skyclarys revenue hit $130.3 million, up from $100 million last year. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
ROCKVILLE, Md., July 31, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN ( "Supernus" ) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. SAGE ( "Sage" ) .
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( zuranolone ) , and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base Acquisition ...
Biogen Inc. ( BIIB ) Surpasses Q2 Earnings and Revenue Estimates
Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
Ionis ( IONS ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, July 29, 2025 at 8 p.m. ETChief Executive Officer - Brett MoniaContinue reading ...
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference ( AAIC ) 2025
TOKYO and CAMBRIDGE, Mass., July 30, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen" ) announced today that the two-year ...
Biogen ( BIIB ) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
BioMarin Pharmaceutical ( BMRN ) Reports Next Week: Wall Street Expects Earnings Growth
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZURZUVAE® ( zuranolone ) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) adopted a positive opinion recommending marketing authorization for ZURZUVAE® ( zuranolone ) for the ...
Analysts Estimate Biogen Inc. ( BIIB ) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rheumatologists Eye AbbVie's Rinvoq, Roche/Genentech's Gazyva, and Bristol Myers Squibb's Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
EXTON, PA, July 23, 2025 ( GLOBE NEWSWIRE ) -- Biologic use in systemic lupus erythematosus ( SLE ) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - AstraZeneca ( NASDAQ:AZN )
AstraZeneca plans $50 billion in U.S. investment by 2030, including a drug facility in Virginia for its metabolic and weight loss portfolio. Company aims to generate 50% of $80 billion revenue from the U.S. by 2030 with new manufacturing and R&D expansions.
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Sarepta Therapeutics ( NASDAQ:SRPT ) , Biogen ( NASDAQ:BIIB )
George Tidmarsh has helped bring seven drugs to market and authored 143 scientific works. He criticizes fast-tracked FDA approvals, calling for more regulatory consistency. Tim Melvin's system has spotted 10X winners like NVIDIA and Matador-see his next 6 picks and the options strategies to ...
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference ( AAIC ) , taking place July 27-31 in Toronto, Canada.
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 - Biogen ( NASDAQ:BIIB )
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations ...
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen ( NASDAQ:BIIB )
Biogen to invest $2 billion more in its RTP manufacturing, adding to $10B already spent in North Carolina. Expansion includes advanced automation, AI integration and multi-platform fill finish capabilities.
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
CAMBRIDGE, Mass., July 21, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) - today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park ( RTP ) .
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary - Biogen ( NASDAQ:BIIB )
Investment builds on Biogen's 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc.
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Vor Biopharma ( NASDAQ:VOR )
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio's new development focus and execution of late-stage programs
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
CAMBRIDGE, Mass., July 17, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio ( Nasdaq: VOR ) , a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced ...
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Bristol-Myers Squibb ( NYSE:BMY )
BofA cuts Bristol-Myers Squibb's 2025 EPS and revenue forecast by over 1% but maintains a $56 price target. Analysts expect Q2 adjusted EPS of $1.585 on $11.31 billion in revenue; earnings report due July 31. PPI and Industrial Production drop Wednesday morning - see how Matt Maley is trading ...
What's Driving the Market Sentiment Around Biogen? - Biogen ( NASDAQ:BIIB )
Biogen's BIIB short percent of float has fallen 10.75% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 2.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.57 days to cover their ...
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
Ionis Pharmaceuticals ( IONS ) Moves 9.1% Higher: Will This Strength Last?
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
CAMBRIDGE, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) - announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults ...
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
CAMBRIDGE, Mass., June 27, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy ( SMA ) .
Biogen/Ionis Drug Shows Promise In Children With Spinal Muscular Atrophy - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
Biogen's salanersen cut neurofilament levels by 70% in spinal muscular atrophy patients previously treated with Zolgensma. 50% of children with spinal muscular atrophy gained new WHO motor milestones after 1 year of salanersen treatment. Ready to turn the market's comeback into steady cash flow?
Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday - Carnival ( NYSE:CCL ) , Biogen ( NASDAQ:BIIB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley raised TD SYNNEX Corporation SNX price target from $145 to $155.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
Salanersen ( BIIB115/ION306 ) is a novel antisense oligonucleotide ( ASO ) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy ( SMA )
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
CAMBRIDGE, Mass., June 25, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced topline results from the Phase 1 study of salanersen ( BIIB115/ION306 ) , an antisense oligonucleotide ( ASO ) being developed for the treatment of spinal muscular atrophy ( SMA ) .
